First Therapeutic Use of Ac-225 at Stanford
On October 23, 2025, Dr. Carina Mari Aparici, Principal Investigator, and Dr. Shagufta Shaheen, co-Principal Investigator, provided the first treatment with Actinium-225 (Ac-225) -an alpha emitter- at Stanford. The therapy was made available to a patient with advanced, inoperable neuroendocrine tumor with recurrent disease after PRRT. This achievement represents an exciting advancement in the field of targeted radionuclide therapy, offering new hope for patients through innovative, molecular-targeted, precision-based treatment strategies.
Pictured: Members of the dedicated multidisciplinary team dedicated administering Cycle 1. From left to right: Carina Mari Aparici, MD, Clinical Professor Nuclear Medicine & Molecular Imaging, Mikayla Easterling, CRC SCI-CTO; Zach Leonard, CNMT Nuclear Medicine & Molecular Imaging.
With many thanks to Scott Jordan, RN (photographer); Cat Hoffman, APP; John Kwofie, MS, Deputy RSO; Christine Wolfe, RN; Donald Samaan, RRPT Health Physics; Brittney Williams, CRM; David Marcellus, interim CRM, Saira Jaffry, AA - and the many others whose efforts made this achievement possible. It truly takes a village!